Neuroimmune Modulation Delivers Two-Year Sustained Relief in Advanced Rheumatoid Arthritis

For adults living with advanced rheumatoid arthritis, exhausting the available pharmaceutical options often means resigning to chronic pain, profound fatigue, and progressive joint destruction. A novel approach that uses targeted electrical impulses rather than systemic drugs is now demonstrating that durable, long-term disease control is possible.

At the American College of Rheumatology Convergence 2026 in Orlando, Florida, researchers presented 24-month follow-up data from the pivotal RESET-RA trial. The results confirm that an implantable vagus nerve stimulator provides sustained, and in many cases improving, clinical relief for patients who have failed multiple advanced therapies.[1][2][3]

The data, presented on November 10, 2026, by Dr. John R.P. Tesser of Arizona Arthritis & Rheumatology Associates, marks a significant milestone for the emerging field of bioelectronic medicine. The findings show that the SetPoint System maintains its efficacy over two years without the waning response frequently seen with biologic medications.[2][3]

Breaking the Medication Cycle

Rheumatoid arthritis is a systemic autoimmune disease characterized by runaway inflammation that attacks the synovial lining of the joints. Standard treatment relies heavily on biologic and targeted synthetic disease-modifying antirheumatic drugs, a category that includes tumor necrosis factor inhibitors and Janus kinase inhibitors.[4]

While these medications have revolutionized rheumatology over the last two decades, they are not universally effective. A substantial portion of patients either do not respond adequately, lose their response over time as their bodies develop neutralizing antibodies, or cannot tolerate the side effects of systemic immunosuppression.[4]

"Patients with rheumatoid arthritis need novel treatment options that can provide durable disease control over the long term," said Dr. David Chernoff, chief medical officer of SetPoint Medical. For the highly treatment-experienced population enrolled in the RESET-RA trial, finding an effective, lasting intervention had previously proved elusive.[3]

The cycle of switching from one biologic to another carries significant physical and financial costs. Patients often endure months of uncontrolled inflammation while waiting to see if a new drug will work, accumulating irreversible joint damage and facing an increased risk of severe opportunistic infections.[4]

Harnessing the Inflammatory Reflex

The SetPoint System, which received landmark approval from the U.S. Food and Drug Administration in July 2025, bypasses traditional pharmacological pathways entirely. Instead, it targets the body's innate neuroimmune network through a physiological mechanism known as the inflammatory reflex.[2][3]

The vagus nerve, a major cranial nerve connecting the brainstem to the abdomen, acts as a natural brake on the immune system. When activated, it signals the spleen and other organs to regulate the production of proinflammatory cytokines, maintaining a healthy immunological balance.[4]

In patients with rheumatoid arthritis, this reflex is chronically dysregulated, and tonic vagus nerve activity is diminished. Actively stimulating the nerve engages the reflex, resulting in the release of acetylcholine and the specific agonism of α7 nicotinic acetylcholine receptors on immune cells, particularly macrophages.[4]

This highly specific receptor activation downregulates the production of the exact cytokines driving the disease, including tumor necrosis factor, interleukin-1β, and interleukin-6. Because the therapy modulates the immune response neurologically rather than chemically, it lowers inflammation without broadly suppressing the patient's entire immune system.[4]

During a 60-to-90-minute outpatient procedure, surgeons implant the miniaturized SetPoint device directly onto the left cervical vagus nerve. Once activated by a rheumatologist, the integrated, leadless stimulator delivers exactly one minute of targeted electrical stimulation per day, requiring only a few minutes of wireless charging each week.[3][5]

Two Years of Sustained Efficacy

The RESET-RA trial originally enrolled 242 adults across 41 international clinical sites. All participants had moderately to severely active rheumatoid arthritis and had previously experienced an inadequate response or intolerance to at least one biologic or targeted synthetic disease-modifying drug, making them a difficult-to-treat cohort.[1][5]

Following a blinded, sham-controlled primary phase that proved early efficacy, participants entered an open-label extension where all received active daily stimulation. The newly presented 24-month data reveal remarkable therapy persistence, with 91.7 percent of patients choosing to continue the daily neurostimulation at the two-year mark.[3]

The clinical benefits proved highly durable, defying the gradual loss of efficacy that plagues many pharmaceutical interventions. According to the data presented at the rheumatology meeting, 71 percent of study participants reached the 24-month follow-up without needing to add a new biologic or targeted synthetic medication to their regimen.[3]

Among those receiving the stimulation therapy without additional advanced medications, clinical response rates steadily improved over the two-year period. At 24 months, 62.7 percent of these patients achieved an ACR20 response, representing a validated 20 percent improvement in tender and swollen joint counts alongside other core disease markers.[2][3]

Deeper, more profound clinical responses were also common in this refractory cohort. The data showed that 38.7 percent achieved an ACR50 response, and 18.7 percent reached an ACR70 response, indicating a 70 percent overall improvement in their rheumatoid arthritis symptoms and physical function.[2][3]

Furthermore, approximately half of the participants attained low disease activity or full clinical remission based on the Disease Activity Score 28 using C-reactive protein. Overall, 77.7 percent achieved a good or moderate response according to European Alliance of Associations for Rheumatology criteria.[3]

Preserving Joints and Ensuring Safety

Beyond symptomatic relief, earlier data from the RESET-RA trial demonstrated that the neuroimmune modulation therapy actively protects skeletal architecture. Magnetic resonance imaging analysis showed that the SetPoint System significantly inhibited the progression of joint erosions as early as three months following device activation.[3]

"These 24-month data show that a large majority of patients maintained meaningful clinical responses without having to add biologics or JAK inhibitors, while continuing to demonstrate a favorable safety profile," Chernoff noted in a statement following the presentation.[3]

The long-term safety data align seamlessly with the initial trial results published in the journal Nature Medicine. Because the device does not rely on systemic immunosuppression, patients avoid the elevated infection risks, liver toxicity, and cardiovascular warnings that accompany many advanced pharmaceutical therapies.[4]

Adverse events related to the therapy were primarily surgical and localized. During the initial perioperative period, 1.6 percent of patients experienced a related serious adverse event, all of which resolved completely. The most common side effect was mild to moderate hoarseness associated with the implantation procedure.[2][4]

AI

The Future of Bioelectronic Medicine

The success of the SetPoint System at the two-year mark provides the strongest clinical evidence to date that neuroimmune modulation can serve as a primary pillar of autoimmune care. It represents a fundamental shift from chemical interventions to precision electroceuticals.[2]

"Durable responses at two years, alongside a consistent safety profile and high rates of patients remaining on therapy, reinforce the role of the SetPoint System," said Murthy V. Simhambhatla, chief executive officer of SetPoint Medical. The company plans to expand patient access across the United States throughout 2027.[2][3]

The economic implications of a durable, device-based treatment are substantial. By reducing the reliance on high-cost biologic infusions and frequent medication changes, neuroimmune modulation offers a potentially cost-effective long-term strategy for managing a disease that places a massive financial burden on healthcare systems.[2]

While the current FDA approval is specific to rheumatoid arthritis, the clinical validation of the inflammatory reflex opens the door for much broader applications. Researchers are already investigating whether similar vagus nerve stimulation could effectively treat other immune-mediated conditions, including multiple sclerosis and Crohn's disease.[2]

For now, the 24-month RESET-RA data confirm that for patients who have run out of pharmaceutical options, a one-minute daily electrical pulse can restore joint function, halt structural damage, and preserve long-term quality of life.[1][2][3]